Home › Linfoma follicolare › New York › New York City
Studi clinici su Linfoma follicolare a New York City, NY
24 studi su Linfoma follicolare cercano partecipanti presso sedi a New York City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
In reclutamentoFase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
In reclutamentoFase 1/2
- Research Site, New York
- Research Site, New York
Epco, Zanu, Ritux for R/R FL or MZL
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
In reclutamentoFase 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
In reclutamentoFase 1
- Columbia University, New York
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
In reclutamentoFase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
In reclutamentoFase 2
- Research Site, New York
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
In reclutamentoFase 3
- Mount Sinai Medical Center, New York
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
In reclutamentoFase 3
- Icahn School of Medicine at Mt Sinai, New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
In reclutamentoFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
In reclutamentoFase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- e altri 1
A Study of ARC-02 in B-cell NHL
In reclutamentoFase 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
In reclutamentoFase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
In reclutamento
- New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS), New York
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center, New York
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center - Bergen, New York
Chronic CED of TPT for Recurrent Malignant Glioma
In reclutamentoFase 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
Epcoritamab and Rituximab for First-line Follicular Lymphoma
In reclutamentoFase 2
- Icahn School of Medicine at Mount Sinai Hospital, New York
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
In reclutamentoFase 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
In reclutamentoFase 3
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of SGR-1505 in Mature B-Cell Neoplasms
In reclutamentoFase 1
- Weill Cornell, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, New York
Studi su Linfoma follicolare in altre città
- Milwaukee, WI19 studi
- Nashville, TN18 studi
- Houston, TX18 studi
- Boston, MA17 studi
- Baldwin Park, CA16 studi
- Seattle, WA15 studi
- Durham, NC15 studi
- Salt Lake City, UT13 studi
- Columbus, OH13 studi
- Chicago, IL12 studi
- San Antonio, TX12 studi
- Philadelphia, PA12 studi
Altri studi a New York City
- Cancro al seno136 studi
- Cancro del polmone non a piccole cellule121 studi
- Cancro (tutti i tipi)109 studi
- Cancro alla prostata103 studi
- Cancro metastatico93 studi
- Cancro colorettale78 studi
- Cancro ovarico69 studi
- Cancro ai polmoni60 studi
- Mieloma multiplo60 studi
- Cancro pancreatico60 studi
- Cancro dell'endometrio52 studi
- Leucemia mieloide acuta51 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.